drugset / Trial / NCT00892840

Multiple-Ascending Dose Study

NCT00892840

Phase 1 Completed 57 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and tolerability of BMS-820836 after multiple doses

Timeline

Start
2009-05
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Liafensine Small molecule 0.1 mg Oral
Subject Liafensine Small molecule 4 mg Oral

Indications